AI Predicts Metastasis Risk in Prostate Cancer: Revolutionary Biomarker
ArteraAI has announced the validation of its AI-based digital pathology biomarker for predicting metastasis risk in prostate cancer patients...
Search results for:
risk based
GRAIL Unveils Innovative Risk Classification Test for Lung Cancer Study
GRAIL, LLC, a pioneering healthcare company dedicated to early cancer detection for potential curative treatment, has partnered with AstraZeneca...
Roche on RBQM and AI in Clinical Trials: Secrets to Success
In this interview, Michael Torok, Head of Quality Assurance Programs at Roche, delves into the operationalization of RBQM (Risk...
GSK Leaders Unveil Innovative RBQM Approach: Human Aspect
In an era where clinical trials have become increasingly complex, the significance of human-centric risk management was brought to...
Beigene’s Global MAT2A Inhibitor Licensing Deal
BeiGene, soon to be BeOne Medicines, has secured global licensing rights for SYH2039, a novel MAT2A inhibitor, from CSPC....
Tobevibart & Elebsiran Get Breakthrough & PRIME for Chronic Hep D
Tobevibart and elebsiran, developed by Vir Biotechnology for chronic hepatitis delta (CHD), have received Breakthrough Therapy designation from the...
Envision Trial Shows UGN-102’s Potential for LG-IR-NMIBC Treatment
UroGen Pharma announced positive Phase 3 ENVISION trial results for UGN-102, a mitomycin-based intravesical solution for recurrent low-grade intermediate-risk...
Daiichi Sankyo’s Oncology Breakthroughs at ESMO Asia, SABCS & ASH
Daiichi Sankyo will present over 45 abstracts showcasing new clinical research in various cancers at the 2024 ESMO Asia...
Daiichi Sankyo Oncology Progress at ESMO Asia, SABCS & ASH
Daiichi Sankyo will present over 45 abstracts showcasing new clinical research across its oncology portfolio at the 2024 ESMO...
EU Approves Tevimbra for Esophageal and Gastric Cancer
The European Commission approved BeiGene’s tislelizumab (TEVIMBRA), combined with chemotherapy, for first-line treatment of esophageal squamous cell carcinoma (ESCC)...